APC and prostate carcinoma: Reduces global 5mC content, through inhibition of DNMT1 activity on hemimethylated substrates. Decreases methylation in APC and RARB gene promoters, thus increasing re-expression. Inhibits growth and clonogenic survival of prostate cancer cell lines.